“We are thrilled about our new partnership with AliveDx, which enables us to distribute the innovative MosaiQ multiplexing microarray assay technology for diagnosing autoimmune diseases. This collaboration marks a significant milestone for BioAnalytica as we join forces with a company renowned for its excellence, commitment to quality, and cutting-edge technology. Together, we aim to expand our reach, enhance our service offerings, and bring even greater value to our customers. We look forward to a prosperous and successful partnership focused on advancing autoimmunity solutions with the latest technological innovations”
Stavros Souyannis, CEO of BioAnalytica S.A.

“We are proud to announce our partnership with another key player in the European Union. We look forward to collaborating with BioAnalytica and supporting laboratorians, clinicians, and patients in the region”
Manuel O. Méndez, CEO AliveDx

This collaboration will allow both parties to enhance patient care and deliver high-quality services to the healthcare sector in Southern Europe.

The MosaiQ platform simplifies workflows and creates efficiencies thanks to its multiplexing microarray assay technology. This streamlined and efficient approach offers faster and more cost-effective solutions to healthcare providers and patients alike.